Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 22;25(2):bbad527.
doi: 10.1093/bib/bbad527.

The landscape of the methodology in drug repurposing using human genomic data: a systematic review

Lijuan Wang  1   2 , Ying Lu  2 , Doudou Li  2 , Yajing Zhou  2 , Lili Yu  2 , Ines Mesa Eguiagaray  1 , Harry Campbell  1 , Xue Li  2 , Evropi Theodoratou  1   3
Affiliations

The landscape of the methodology in drug repurposing using human genomic data: a systematic review

Lijuan Wang et al. Brief Bioinform. .

Abstract

The process of drug development is expensive and time-consuming. In contrast, drug repurposing can be introduced to clinical practice more quickly and at a reduced cost. Over the last decade, there has been a significant expansion of large biobanks that link genomic data to electronic health record data, public availability of various databases containing biological and clinical information and rapid development of novel methodologies and algorithms in integrating different sources of data. This review aims to provide a thorough summary of different strategies that utilize genomic data to seek drug-repositioning opportunities. We searched MEDLINE and EMBASE databases to identify eligible studies up until 1 May 2023, with a total of 102 studies finally included after two-step parallel screening. We summarized commonly used strategies for drug repurposing, including Mendelian randomization, multi-omic-based and network-based studies and illustrated each strategy with examples, as well as the data sources implemented. By leveraging existing knowledge and infrastructure to expedite the drug discovery process and reduce costs, drug repurposing potentially identifies new therapeutic uses for approved drugs in a more efficient and targeted manner. However, technical challenges when integrating different types of data and biased or incomplete understanding of drug interactions are important hindrances that cannot be disregarded in the pursuit of identifying novel therapeutic applications. This review offers an overview of drug repurposing methodologies, providing valuable insights and guiding future directions for advancing drug repurposing studies.

Keywords: drug repurposing; genetic variants; methodology; systematic review.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Waring MJ, Arrowsmith J, Leach AR, et al. . An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov 2015;14:475–86. - PubMed
    1. Rautio J, Kumpulainen H, Heimbach T, et al. . Prodrugs: design and clinical applications. Nat Rev Drug Discov 2008;7:255–70. - PubMed
    1. Berdigaliyev N, Aljofan M. An overview of drug discovery and development. Future Med Chem 2020;12:939–47. - PubMed
    1. Reay WR, Cairns MJ. Advancing the use of genome-wide association studies for drug repurposing. Nat Rev Genet 2021;22:658–71. - PubMed
    1. Pushpakom S, Iorio F, Eyers PA, et al. . Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 2019;18:41–58. - PubMed

Publication types

LinkOut - more resources